International Journal of Hematology

DOI: 10.1007/s12185-011-0917-5 Pages: 344-354

Novel therapies in MM: from the aspect of preclinical studies

1. Dana-Farber Cancer Institute and Harvard Medical School, Department of Medical Oncology

Correspondence to:
Teru Hideshima
Tel: +1-617-6322144
Fax: +1-617-6322140



During the last decade, thalidomide, lenalidomide, and bortezomib have been approved by the US Food and Drug Administration for the treatment of MM; however, MM remains incurable. The development and progression of multiple myeloma (MM) is a complex multi-step process involving genetic abnormalities in tumor cells at both early and late stages. Moreover, soluble factors and cell–cell contact within the tumor bone marrow (BM) microenvironment promotes MM cell growth, survival, and drug resistance. A number of novel agents targeting both tumor cells and growth factors in the BM milieu have been developed. Currently they are under evaluation in preclinical studies, as single agents and/or in combination, to improve outcome of MM patients.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge